Financial Personal
Corstasis Therapeutics to Present Pivotal Trial Data on Novel Bumetanide Nasal Spray at American Heart Association Scientific Sessions 2024
New data highlights the safety and efficacy of a new outpatient self-administered therapy intended to assist in the management of fluid overload in CHF, liver, and kidney disease patients HENDERSON, Nev. — Corstasis Therapeutics Inc., a clinica
New data highlights the safety and efficacy of a new outpatient self-administered therapy intended to assist in the management of fluid overload in CHF, liver, and kidney disease patients Read More
